Nakai Shigeru, Wada Atsushi, Kitaoka Tateki, Shinzato Takahiro, Nagura Yuji, Kikuchi Kenjiro, Masakane Ikuto, Shinoda Toshio, Yamazaki Chikao, Sakai Rumi, Marubayashi Seiji, Morita Osamu, Iseki Kunitoshi, Usami Takeshi, Kimata Naoki, Suzuki Kazuyuki, Tabei Kaoru, Fushimi Kiyohide, Miwa Naoko, Yauchi Mitsuru, Wakai Kenji, Akiba Takashi
Patient Registration Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan.
Ther Apher Dial. 2006 Dec;10(6):476-97. doi: 10.1111/j.1744-9987.2006.00440.x.
A statistical survey of 3932 nationwide hemodialysis (hereafter, dialysis) facilities was carried out at the end of 2004, and 3882 facilities (98.73%) responded. The population undergoing dialysis at the end of 2004 was 248 166, an increase of 10 456 patients (4.4%) from that at the end of 2003. The number of dialysis patients per million people was 1943.5. The crude death rate of dialysis patients from the end of 2003 to the end of 2004 was 9.4%. The mean age of patients who underwent dialysis in 2004 was 65.8 years, and that of the total dialysis population was 63.3 years. The percentage distribution of patients who underwent dialysis according to a newly underlying disease showed that 41.3% of patients had diabetic nephropathy and 28.1% had chronic glomerulonephritis. The frequency of calcium carbonate use for dialysis patients was 75.1% and that of sevelamer hydrochloride use was 26.2%. The frequency of sevelamer hydrochloride use does not necessarily have a strong correlation with the dose of calcium carbonate. Patients who received high doses of sevelamer hydrochloride tended to have a low concentration of arterial blood HCO(3-). Approximately 15% of dialysis patients used an intravenous vitamin D preparation, generally maxacalcitol. The longer the patients had been on dialysis, the higher the frequency of use of an intravenous vitamin D preparation. When the concentration of serum intact parathyroid hormone (PTH) was more than 200 pg/mL, the frequency of use of an orally administered vitamin D preparation decreased; but that of intravenous vitamin D preparation increased. The percentage of dialysis patients who received percutaneous ethanol injection therapy (PEIT) was 1.4%. The percentage was more than 50% in the patients who had been on dialysis for more than 10 years. The percentage of patients who received PEIT again was 35.0%. The percentage of patients who had been on hemodialysis for more than 10 years and received PEIT again was more than 50%.
2004年末对全国3932家血液透析（以下简称透析）机构进行了统计调查，3882家机构（98.73%）予以回应。2004年末接受透析治疗的患者人数为248166人，比2003年末增加了10456名患者（4.4%）。每百万人口中透析患者人数为1943.5人。2003年末至2004年末透析患者的粗死亡率为9.4%。2004年接受透析治疗患者的平均年龄为65.8岁，透析患者总体平均年龄为63.3岁。根据新的基础疾病分类，接受透析治疗患者的百分比分布显示，41.3%的患者患有糖尿病肾病，28.1%的患者患有慢性肾小球肾炎。透析患者使用碳酸钙的频率为75.1%，使用盐酸司维拉姆的频率为26.2%。盐酸司维拉姆的使用频率与碳酸钙剂量不一定有很强的相关性。接受高剂量盐酸司维拉姆的患者往往动脉血HCO(3-)浓度较低。约15%的透析患者使用静脉注射维生素D制剂，通常为maxacalcitol。患者透析时间越长，静脉注射维生素D制剂的使用频率越高。当血清完整甲状旁腺激素（PTH）浓度超过200 pg/mL时，口服维生素D制剂的使用频率降低；但静脉注射维生素D制剂的使用频率增加。接受经皮乙醇注射治疗（PEIT）的透析患者百分比为1.4%。透析超过10年的患者中该百分比超过50%。再次接受PEIT治疗的患者百分比为35.0%。血液透析超过10年且再次接受PEIT治疗的患者百分比超过50%。
